Peers of Inhibikase Therapeutics Inc (IKT)
Side-by-side comparison
Health Care · Biotechnology
Enterprise value divided by trailing twelve-month revenue. A capital-structure-neutral sales valuation metric.
Latest EV/Sales
6.34x
As of Sep 27, 2024
Beyond EV/Sales, the valuation view includes forward multiples, EV ratios, cash flow yields, and multi-year chart history for further research.
| Date | EV/Sales |
|---|---|
| Sep 27, 2024 | 6.34x |
| Sep 26, 2024 | 4.54x |
| Sep 25, 2024 | 2.73x |
| Sep 24, 2024 | 4.54x |
| Sep 23, 2024 | 6.34x |
| Sep 20, 2024 | 9.05x |
| Sep 19, 2024 | 5.44x |
| Sep 18, 2024 | 6.34x |
EV/Sales = Enterprise Value / Revenue (TTM). Enterprise Value = Market Cap + Total Debt − (Cash & Short-Term Investments + Long-Term Investments).
EV/Sales is particularly useful in M&A analysis and for companies with significant debt.
Read the general EV/Sales definition, formula, and analyst usage guide.
EV/Sales guideInformational research only; not personalized advice. Values reflect the latest available data on Chartloom and may differ from other sources.
Side-by-side comparison